Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of the Efficacy and Safety of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

NCT07110415 is registered in ClinicalTrials.gov with SPH Qingdao Growful Pharmacetical Co.,Ltd as lead sponsor.

NCT NCT07110415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07110415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of the Efficacy and Safety of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
Lead sponsor
SPH Qingdao Growful Pharmacetical Co.,Ltd
Phase
Phase 4
Overall status
Recruiting
Start date
November 6, 2025
Completion date
December 31, 2030
Enrollment
2,708 (estimated)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac dysfunction, coronary heart disease